Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1915.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,877.0,1.0,=,2.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1170.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,604.0,1.0,=,1.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,672.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,219.0,1.0,=,3.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,571.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,364.0,1.0,=,1.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3338.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,1245.0,1.0,=,2.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3486.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,591.0,1.0,=,5.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2294.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,654.0,1.0,=,3.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,697.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,228.0,1.0,=,3.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2572.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,1366.0,1.0,=,1.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,939.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,145.0,1.0,=,6.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1445.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,161.0,1.0,=,9.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2205.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,413.0,1.0,=,5.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1689.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,918.0,1.0,=,1.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3189.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,1045.0,1.0,=,3.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1352.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,456.0,1.0,=,3.0